Romiplostim is a biologic agent that mimics the action of thrombopoietin, a natural hormone responsible for regulating platelet production. It binds to and activates the thrombopoietin receptor on the surface of megakaryocytes and their precursors, promoting their maturation and increasing platelet production. This mechanism is crucial for patients with cancer who might experience reduced platelet counts due to their disease or its treatment.
